BG64541B1 - Фармацевтични състави,съдържащи ламивудин и зидовудин, и използването им - Google Patents

Фармацевтични състави,съдържащи ламивудин и зидовудин, и използването им Download PDF

Info

Publication number
BG64541B1
BG64541B1 BG103435A BG10343599A BG64541B1 BG 64541 B1 BG64541 B1 BG 64541B1 BG 103435 A BG103435 A BG 103435A BG 10343599 A BG10343599 A BG 10343599A BG 64541 B1 BG64541 B1 BG 64541B1
Authority
BG
Bulgaria
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
lamivudine
zidovudine
amount
Prior art date
Application number
BG103435A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103435A (en
Inventor
Gary Goodson
Allen Wood
Katherine Ford
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of BG103435A publication Critical patent/BG103435A/xx
Publication of BG64541B1 publication Critical patent/BG64541B1/bg

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BG103435A 1996-10-31 1999-05-26 Фармацевтични състави,съдържащи ламивудин и зидовудин, и използването им BG64541B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622681.6A GB9622681D0 (en) 1996-10-31 1996-10-31 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
BG103435A BG103435A (en) 2000-04-28
BG64541B1 true BG64541B1 (bg) 2005-07-29

Family

ID=10802224

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103435A BG64541B1 (bg) 1996-10-31 1999-05-26 Фармацевтични състави,съдържащи ламивудин и зидовудин, и използването им

Country Status (44)

Country Link
EP (1) EP0941100B1 (es)
JP (1) JP2001502718A (es)
KR (1) KR100551652B1 (es)
AP (1) AP1067A (es)
AR (1) AR009135A1 (es)
AT (1) ATE241364T1 (es)
AU (1) AU736607B2 (es)
BG (1) BG64541B1 (es)
BR (1) BR9712614A (es)
CA (1) CA2270174A1 (es)
CO (1) CO4930269A1 (es)
CY (1) CY2485B1 (es)
CZ (1) CZ296080B6 (es)
DE (1) DE69722433T2 (es)
DK (1) DK0941100T3 (es)
EA (1) EA002437B1 (es)
EE (1) EE03806B1 (es)
ES (1) ES2200204T3 (es)
GB (1) GB9622681D0 (es)
GE (1) GEP20022735B (es)
GT (1) GT199700116A (es)
HK (1) HK1020880A1 (es)
HR (1) HRP970569B1 (es)
HU (1) HU224969B1 (es)
ID (1) ID18698A (es)
IL (1) IL129422A0 (es)
IS (1) IS5024A (es)
MY (1) MY119513A (es)
NO (1) NO317163B1 (es)
NZ (1) NZ335153A (es)
OA (1) OA11038A (es)
PA (1) PA8441101A1 (es)
PE (1) PE10099A1 (es)
PL (1) PL190349B1 (es)
PT (1) PT941100E (es)
SI (1) SI0941100T1 (es)
SK (1) SK284286B6 (es)
SV (1) SV1997000090A (es)
TR (1) TR199900950T2 (es)
UA (1) UA64725C2 (es)
UY (1) UY24766A1 (es)
WO (1) WO1998018477A2 (es)
YU (1) YU19999A (es)
ZA (1) ZA979726B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
DE60219965T2 (de) * 2002-04-23 2008-01-17 Lupin Ltd., Mumbai Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
DE60313657T2 (de) * 2002-11-08 2008-01-03 Smithkline Beecham Corp. Antivirale zusammensetzungen
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
WO2011156594A2 (en) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
CN104203244A (zh) 2012-03-05 2014-12-10 希普拉有限公司 包含拉米夫定、festinnvir和奈韦拉平的抗反转录病毒药物组合物
WO2014130553A2 (en) * 2013-02-20 2014-08-28 Abbvie Inc. Tablet dosage forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
WO1992020344A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
GB9110624D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Combinations
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
CO4930269A1 (es) 2000-06-27
SV1997000090A (es) 1998-10-07
IS5024A (is) 1999-04-09
NO992091D0 (no) 1999-04-29
EE03806B1 (et) 2002-08-15
BR9712614A (pt) 1999-10-26
AU5314298A (en) 1998-05-22
EP0941100B1 (en) 2003-05-28
TR199900950T2 (xx) 1999-07-21
ZA979726B (en) 1999-04-29
EP0941100A2 (en) 1999-09-15
WO1998018477A2 (en) 1998-05-07
PL190349B1 (pl) 2005-11-30
PE10099A1 (es) 1999-03-02
NO992091L (no) 1999-06-29
EA199900345A1 (ru) 2000-02-28
AP1067A (en) 2002-05-01
CZ155799A3 (cs) 1999-10-13
CA2270174A1 (en) 1998-05-07
AP9901519A0 (en) 1999-06-30
UY24766A1 (es) 2000-12-29
ES2200204T3 (es) 2004-03-01
BG103435A (en) 2000-04-28
CY2485B1 (en) 2005-06-03
JP2001502718A (ja) 2001-02-27
IL129422A0 (en) 2000-02-17
PL333143A1 (en) 1999-11-22
CZ296080B6 (cs) 2006-01-11
UA64725C2 (uk) 2004-03-15
ID18698A (id) 1998-04-30
OA11038A (en) 2002-02-06
AU736607B2 (en) 2001-08-02
GB9622681D0 (en) 1997-01-08
HRP970569B1 (en) 2004-10-31
KR20000052893A (ko) 2000-08-25
KR100551652B1 (ko) 2006-02-13
MY119513A (en) 2005-06-30
SK57599A3 (en) 2000-06-12
DE69722433D1 (de) 2003-07-03
ATE241364T1 (de) 2003-06-15
WO1998018477A3 (en) 1998-06-18
NZ335153A (en) 2001-04-27
DE69722433T2 (de) 2004-04-08
NO317163B1 (no) 2004-08-30
GEP20022735B (en) 2002-07-25
AR009135A1 (es) 2000-03-08
SI0941100T1 (en) 2003-12-31
EA002437B1 (ru) 2002-04-25
DK0941100T3 (da) 2003-09-01
HUP0000344A3 (en) 2002-04-29
SK284286B6 (sk) 2005-01-03
EE9900175A (et) 1999-12-15
GT199700116A (es) 1999-04-22
HU224969B1 (en) 2006-04-28
HUP0000344A2 (hu) 2001-05-28
HRP970569A2 (en) 1998-08-31
HK1020880A1 (en) 2000-05-26
PA8441101A1 (es) 2000-05-24
PT941100E (pt) 2003-10-31
YU19999A (sh) 2000-10-30

Similar Documents

Publication Publication Date Title
CA2633603C (en) Pharmaceutical combination
HUE035241T2 (en) Darunavir combination products
CA2330391A1 (en) Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
BG64541B1 (bg) Фармацевтични състави,съдържащи ламивудин и зидовудин, и използването им
KR20200070246A (ko) 이중층 제약 정제 제제
EP1567133B1 (en) Pharmaceutical antiviral compositions
US20050171127A1 (en) Pharmaceutical compositions comprising abacavir and lamivudine
US20030004130A1 (en) Homogeneous pharmaceutical compositions containing zidovudine and lamivudine
MXPA99004025A (es) Composiciones farmaceuticas que contienen lamivudina y zidovudina
US20050113394A1 (en) Pharmaceutical compositions
WO2022132676A1 (en) Mini-tablet dosage form of a viral terminase inhibitor and uses thereof
MXPA00010498A (es) Composiciones farmaceuticas homogeneas que comprenden abacavir, lamivudina y zidovudina
CZ20003998A3 (cs) Farmaceutický prostředek